Global Novel Coronavirus (COVID-19) Vaccine Market Size, Status and Forecast 2024-2031

Report ID: 919722 | Published Date: Sep 2024 | No. of Page: 129 | Base Year: 2023 | Rating: 4.6 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Type (2021-2027)
        1.2.2 DNA
        1.2.3 RNA
        1.2.4 Others
    1.3 Market by Application
        1.3.1 Global Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2021-2027)
        1.3.2 Mild Symptom Patient
        1.3.3 Critically Ill Patient
    1.4 Study Objectives
    1.5 Years Considered

2 Executive Summary
    2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size
     2.2 Novel Coronavirus (COVID-19) Vaccine Market Size by Regions
        2.2.1 Novel Coronavirus (COVID-19) Vaccine Growth Rate by Regions (2021-2027)
        2.2.2 Novel Coronavirus (COVID-19) Vaccine Market Share by Regions (2021-2027)
    2.3 Industry Trends
        2.3.1 Market Top Trends
        2.3.2 Market Use Cases

3 Key Players
    3.1 Novel Coronavirus (COVID-19) Vaccine Revenue by Players (2020-2021)
    3.2 Novel Coronavirus (COVID-19) Vaccine Key Players Headquaters and Area Served
    3.3 Key Players Novel Coronavirus (COVID-19) Vaccine Product/Solution/Service
    3.4 Date of Enter into Novel Coronavirus (COVID-19) Vaccine Market
    3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown by Type and by Application
    4.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2021-2027)
    4.2 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2021-2027)

5 North America
   5.1 North America Novel Coronavirus (COVID-19) Vaccine Market Forecast (2021-2027)
    5.2 Novel Coronavirus (COVID-19) Vaccine Key Players in North America
    5.3 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Type
    5.4 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Application
        6.4.4 Canada

6 Europe
    6.1 Europe Novel Coronavirus (COVID-19) Vaccine Market Forecast (2021-2027)
    6.2 Novel Coronavirus (COVID-19) Vaccine Key Players in Europe
    6.3 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Type
    6.4 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Application

7 Japan
    7.1 Japan Novel Coronavirus (COVID-19) Vaccine Market Forecast (2021-2027)
    7.2 Novel Coronavirus (COVID-19) Vaccine Key Players in Europe
    7.3 Japan Novel Coronavirus (COVID-19) Vaccine Market Size by Type
    7.4 Japan Novel Coronavirus (COVID-19) Vaccine Market Size by Application

8 Rest of World
    8.1 China
        8.1.1 China Novel Coronavirus (COVID-19) Vaccine Market Analysis
        8.1.2 Key Players in China
    8.2 Southeast Asia
        8.2.1 Southeast Asia Novel Coronavirus (COVID-19) Vaccine Market Analysis
        8.2.2 Key Players in Southeast Asia
    8.3 India
        8.3.1 India Novel Coronavirus (COVID-19) Vaccine Market Analysis
        8.3.2 Key Players in India


9 International Player Profiles
    9.1 Inovio Pharmaceuticals
        9.1.1 Inovio Pharmaceuticals Company Details
        9.1.2 Inovio Pharmaceuticals Description and Business Overview
        9.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Introduction
        9.1.4 Inovio Pharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.1.5 Inovio Pharmaceuticals Recent Development
    9.2 Takis Biotech (Evvivax)
        9.2.1 Takis Biotech (Evvivax) Company Details
        9.2.2 Takis Biotech (Evvivax) Description and Business Overview
        9.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Introduction
        9.2.4 Takis Biotech (Evvivax) Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.2.5 Takis Biotech (Evvivax) Recent Development
    9.3 Zydus Cadila
        9.3.1 Zydus Cadila Company Details
        9.3.2 Zydus Cadila Description and Business Overview
        9.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Introduction
        9.3.4 Zydus Cadila Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.3.5 Zydus Cadila Recent Development
    9.4 Codagenix, Inc.
        9.4.1 Codagenix, Inc. Company Details
        9.4.2 Codagenix, Inc. Description and Business Overview
        9.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
        9.4.4 Codagenix, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.4.5 Codagenix, Inc. Recent Development
    9.5 GeoVax, Inc.
        9.5.1 GeoVax, Inc. Company Details
        9.5.2 GeoVax, Inc. Description and Business Overview
        9.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
        9.5.4 GeoVax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.5.5 GeoVax, Inc. Recent Development
    9.6 Bravovax
        9.6.1 Bravovax Company Details
        9.6.2 Bravovax Description and Business Overview
        9.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Introduction
        9.6.4 Bravovax Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.6.5 Bravovax Recent Development
    9.7 Janssen Pharmaceutical Companies
        9.7.1 Janssen Pharmaceutical Companies Company Details
        9.7.2 Janssen Pharmaceutical Companies Description and Business Overview
        9.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Introduction
        9.7.4 Janssen Pharmaceutical Companies Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.7.5 Janssen Pharmaceutical Companies Recent Development
    9.8 Altimmune
        9.8.1 Altimmune Company Details
        9.8.2 Altimmune Description and Business Overview
        9.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Introduction
        9.8.4 Altimmune Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.8.5 Altimmune Recent Development
    9.9 Vaxart
        9.9.1 Vaxart Company Details
        9.9.2 Vaxart Description and Business Overview
        9.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Introduction
        9.9.4 Vaxart Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.9.5 Vaxart Recent Development
    9.10 CanSino Biologics
        9.10.1 CanSino Biologics Company Details
        9.10.2 CanSino Biologics Description and Business Overview
        9.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Introduction
        9.10.4 CanSino Biologics Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.10.5 CanSino Biologics Recent Development
    9.11 ExpreS2ion Biotechnologies ApS
        9.11.1 ExpreS2ion Biotechnologies ApS Company Details
        9.11.2 ExpreS2ion Biotechnologies ApS Description and Business Overview
        9.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Introduction
        9.11.4 ExpreS2ion Biotechnologies ApS Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.11.5 ExpreS2ion Biotechnologies ApS Recent Development
    9.12 Clover Biopharmaceuticals
        9.12.1 Clover Biopharmaceuticals Company Details
        9.12.2 Clover Biopharmaceuticals Description and Business Overview
        9.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Introduction
        9.12.4 Clover Biopharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.12.5 Clover Biopharmaceuticals Recent Development
    9.13 GSK
        9.13.1 GSK Company Details
        9.13.2 GSK Description and Business Overview
        9.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Introduction
        9.13.4 GSK Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.13.5 GSK Recent Development
    9.14 Vaxil Bio Ltd.
        9.14.1 Vaxil Bio Ltd. Company Details
        9.14.2 Vaxil Bio Ltd. Description and Business Overview
        9.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Introduction
        9.14.4 Vaxil Bio Ltd. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.14.5 Vaxil Bio Ltd. Recent Development
    9.15 Generex
        9.15.1 Generex Company Details
        9.15.2 Generex Description and Business Overview
        9.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Introduction
        9.15.4 Generex Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.15.5 Generex Recent Development
    9.16 Novavax, Inc.
        9.16.1  Company Details
        9.16.2 Novavax, Inc. Description and Business Overview
        9.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
        9.16.4 Novavax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.16.5 Novavax, Inc. Recent Development
    9.17 Sanofi Pasteur
        9.17.1 Sanofi Pasteur Company Details
        9.17.2 Sanofi Pasteur Description and Business Overview
        9.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Introduction
        9.17.4 Sanofi Pasteur Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.17.5 Sanofi Pasteur Recent Development
    9.18 Baylor
        9.18.1 Baylor Company Details
        9.18.2 Baylor Description and Business Overview
        9.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Introduction
        9.18.4 Baylor Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.18.5 Baylor Recent Development
    9.18 iBio, Inc.
        .1 iBio, Inc. Company Details
        .2 iBio, Inc. Description and Business Overview
        .3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
        .4 iBio, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        .5 iBio, Inc. Recent Development
    9.20 Moderna, Inc.
        9.20.1 Moderna, Inc. Company Details
        9.20.2 Moderna, Inc. Description and Business Overview
        9.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
        9.20.4 Moderna, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.20.5 Moderna, Inc. Recent Development
    9.21 Curevac
        9.21.1 Curevac Company Details
        9.21.2 Curevac Description and Business Overview
        9.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Introduction
        9.21.4 Curevac Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.21.5 Curevac Recent Development
    9.22 ImmunoPrecise
        9.22.1 ImmunoPrecise Company Details
        9.22.2 ImmunoPrecise Description and Business Overview
        9.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Introduction
        9.22.4 ImmunoPrecise Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
        9.22.5 ImmunoPrecise Recent Development

10 Market Dynamics
    10.1 Industry Trends
    10.2 Market Drives
    10.3 Market Challenges
    10.4 Market Restraints

11 Key Findings in This Report
12 Appendix
    12.1 Research Methodology
        12.1.1 Methodology/Research Approach
        12.1.2 Data Source
    12.2 Disclaimer
    12.3 Author Details
List of Tables
    Table 1. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Type (2021-2027) (US$ Million)
    Table 2. Key Players of DNA
    Table 3. Key Players of RNA
    Table 4. Key Players of Others
    Table 5. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth by Application (2021-2027) (US$ Million)
    Table 6. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Regions (2021-2027) (US$ Million)
    Table 7. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Regions (2021-2027)
    Table 8. Market Top Trends
    Table 9. Market Use Cases
    Table 10. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Players (2020-2021) (US$ Million)
    Table 11. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Players (2020-2021)
    Table 12. Key Players Headquarters and Area Served
    Table 13. Key Players Novel Coronavirus (COVID-19) Vaccine Product Solution and Service
    Table 14. Date of Enter into Novel Coronavirus (COVID-19) Vaccine Market
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2021-2027) (US$ Million)
    Table 17. Global Novel Coronavirus (COVID-19) Vaccine Market Size Share by Type (2021-2027)
    Table 18. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2021-2027) (US$ Million)
    Table 19. Global Novel Coronavirus (COVID-19) Vaccine Market Size Share by Application (2021-2027)
    Table 20. North America Key Players Novel Coronavirus (COVID-19) Vaccine Revenue (2020-2021) (US$ Million)
    Table 21. North America Key Players Novel Coronavirus (COVID-19) Vaccine Market Share (2020-2021)
    Table 22. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2021-2027) (US$ Million)
    Table 23. North America Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2021-2027)
    Table 24. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2021-2027) (US$ Million)
    Table 25. North America Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2021-2027)
    Table 26. Europe Key Players Novel Coronavirus (COVID-19) Vaccine Revenue (2020-2021) (US$ Million)
    Table 27. Europe Key Players Novel Coronavirus (COVID-19) Vaccine Market Share (2020-2021)
    Table 28. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2021-2027) (US$ Million)
    Table 29. Europe Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2021-2027)
    Table 30. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2021-2027) (US$ Million)
    Table 31. Europe Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2021-2027)
    Table 32. Japan Key Players Novel Coronavirus (COVID-19) Vaccine Revenue (2020-2021) (US$ Million)
    Table 33. Japan Key Players Novel Coronavirus (COVID-19) Vaccine Market Share (2020-2021)
    Table 34. Japan Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2021-2027) (US$ Million)
    Table 35. Japan Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2021-2027)
    Table 36. Japan Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2021-2027) (US$ Million)
    Table 37. Japan Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2021-2027)
    Table 38. Key Players in China
    Table 39. Key Players in Southeast Asia
    Table 40. Key Players in India
    Table 41. Inovio Pharmaceuticals Company Details
    Table 42. Inovio Pharmaceuticals Description and Business Overview
    Table 43. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product
    Table 44. Inovio Pharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 45. Inovio Pharmaceuticals Recent Development
    Table 46. Takis Biotech (Evvivax) Company Details
    Table 47. Takis Biotech (Evvivax) Description and Business Overview
    Table 48. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product
    Table 49. Takis Biotech (Evvivax) Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 50. Takis Biotech (Evvivax) Recent Development
    Table 51. Zydus Cadila Company Details
    Table 52. Zydus Cadila Description and Business Overview
    Table 53. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product
    Table 54. Zydus Cadila Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 55. Zydus Cadila Recent Development
    Table 56. Codagenix, Inc. Company Details
    Table 57. Codagenix, Inc. Description and Business Overview
    Table 58. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product
    Table 59. Codagenix, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 60. Codagenix, Inc. Recent Development
    Table 61. GeoVax, Inc. Company Details
    Table 62. GeoVax, Inc. Description and Business Overview
    Table 63. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product
    Table 64. GeoVax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 65. GeoVax, Inc. Recent Development
    Table 66. Bravovax Company Details
    Table 67. Bravovax Description and Business Overview
    Table 68. Bravovax Novel Coronavirus (COVID-19) Vaccine Product
    Table 69. Bravovax Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 70. Bravovax Recent Development
    Table 71. Janssen Pharmaceutical Companies Company Details
    Table 72. Janssen Pharmaceutical Companies Description and Business Overview
    Table 73. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product
    Table 74. Janssen Pharmaceutical Companies Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 75. Janssen Pharmaceutical Companies Recent Development
    Table 76. Altimmune Company Details
    Table 77. Altimmune Description and Business Overview
    Table 78. Altimmune Novel Coronavirus (COVID-19) Vaccine Product
    Table 79. Altimmune Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 80. Altimmune Recent Development
    Table 81. Vaxart Company Details
    Table 82. Vaxart Description and Business Overview
    Table 83. Vaxart Novel Coronavirus (COVID-19) Vaccine Product
    Table 84. Vaxart Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 85. Vaxart Recent Development
    Table 86. CanSino Biologics Company Details
    Table 87. CanSino Biologics Description and Business Overview
    Table 88. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product
    Table 89. CanSino Biologics Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 90. CanSino Biologics Recent Development
    Table 91. ExpreS2ion Biotechnologies ApS Company Details
    Table 92. ExpreS2ion Biotechnologies ApS Description and Business Overview
    Table 93. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product
    Table 94. ExpreS2ion Biotechnologies ApS Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 95. ExpreS2ion Biotechnologies ApS Recent Development
    Table 96. Clover Biopharmaceuticals Company Details
    Table 97. Clover Biopharmaceuticals Description and Business Overview
    Table 98. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product
    Table 99. Clover Biopharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 100. Clover Biopharmaceuticals Recent Development
    Table 101. GSK Company Details
    Table 102. GSK Description and Business Overview
    Table 103. GSK Novel Coronavirus (COVID-19) Vaccine Product
    Table 104. GSK Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 105. GSK Recent Development
    Table 106. Vaxil Bio Ltd. Company Details
    Table 107. Vaxil Bio Ltd. Description and Business Overview
    Table 108. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product
    Table 109. Vaxil Bio Ltd. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 110. Vaxil Bio Ltd. Recent Development
    Table 111. Generex Company Details
    Table 112. Generex Description and Business Overview
    Table 113. Generex Novel Coronavirus (COVID-19) Vaccine Product
    Table 114. Generex Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 115. Generex Recent Development
    Table 116. Novavax, Inc. Company Details
    Table 117. Novavax, Inc. Description and Business Overview
    Table 118. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product
    Table 119. Novavax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 120. Novavax, Inc. Recent Development
    Table 121. Sanofi Pasteur Company Details
    Table 122. Sanofi Pasteur Description and Business Overview
    Table 123. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product
    Table 124. Sanofi Pasteur Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 125. Sanofi Pasteur Recent Development
    Table 126. Baylor Company Details
    Table 127. Baylor Description and Business Overview
    Table 128. Baylor Novel Coronavirus (COVID-19) Vaccine Product
    Table 129. Baylor Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 130. Baylor Recent Development
    Table 131. iBio, Inc. Company Details
    Table 132. iBio, Inc. Description and Business Overview
    Table 133. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product
    Table 134. iBio, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 135. iBio, Inc. Recent Development
    Table 136. Moderna, Inc. Company Details
    Table 137. Moderna, Inc. Description and Business Overview
    Table 138. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product
    Table 139. Moderna, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 140. Moderna, Inc. Recent Development
    Table 141. Curevac Company Details
    Table 142. Curevac Description and Business Overview
    Table 143. Curevac Novel Coronavirus (COVID-19) Vaccine Product
    Table 144. Curevac Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 145. Curevac Recent Development
    Table 146. ImmunoPrecise Company Details
    Table 147. ImmunoPrecise Description and Business Overview
    Table 148. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product
    Table 149. ImmunoPrecise Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
    Table 150. ImmunoPrecise Recent Development
    Table 151. Novel Coronavirus (COVID-19) Vaccine Market Trends
    Table 152. Novel Coronavirus (COVID-19) Vaccine Market Drivers
    Table 153. Novel Coronavirus (COVID-19) Vaccine Market Challenges
    Table 154. Novel Coronavirus (COVID-19) Vaccine Market Restraints
    Table 155. Research Programs/Design for This Report
    Table 156. Key Data Information from Secondary Sources
    Table 157. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Type in 2021 & 2027
    Figure 2. DNA Features
    Figure 3. RNA Features
    Figure 4. Others Features
    Figure 5. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Application in 2021 & 2027
    Figure 6. Mild Symptom Patient Case Studies
    Figure 7. Critically Ill Patient Case Studies
    Figure 8. Novel Coronavirus (COVID-19) Vaccine Report Years Considered
    Figure 9. Global Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate (2020-2027) (US$ Million)
    Figure 10. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Regions (2020-2027)
    Figure 11. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Players in 2021
    Figure 12. Global Novel Coronavirus (COVID-19) Vaccine Market Size Market Share by Type (2021-2027)
    Figure 13. Global Novel Coronavirus (COVID-19) Vaccine Market Size Market Share by Application (2021-2027)
    Figure 14. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application in 2021
    Figure 15. North America Novel Coronavirus (COVID-19) Vaccine Market Size 2021-2027 (US$ Million)
    Figure 16. Europe Novel Coronavirus (COVID-19) Vaccine Market Size 2021-2027 (US$ Million)
    Figure 17. Japan Novel Coronavirus (COVID-19) Vaccine Market Size 2021-2027 (US$ Million)
    Figure 18. Novel Coronavirus (COVID-19) Vaccine Market Size in China (2021-2027) (US$ Million)
    Figure 19. Novel Coronavirus (COVID-19) Vaccine Market Size in Southeast Asia (2021-2027) (US$ Million)
    Figure 20. Novel Coronavirus (COVID-19) Vaccine Market Size in India (2021-2027) (US$ Million)
    Figure 21. Bottom-up and Top-down Approaches for This Report
    Figure 22. Data Triangulation
    Figure 23. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix, Inc.
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart
CanSino Biologics
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd.
Generex
Novavax, Inc.
Sanofi Pasteur
Baylor
iBio, Inc.
Moderna, Inc.
Curevac
ImmunoPrecise
Frequently Asked Questions
Novel Coronavirus (COVID-19) Vaccine report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Novel Coronavirus (COVID-19) Vaccine report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Novel Coronavirus (COVID-19) Vaccine report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Software Tools

Market Analysis and Insights: Global Software Tools Market
The global Software Tool ... Read More